(Q37980496)

26 August 2017

title

High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? (English)

1 reference

26 August 2017

0 references

Ernst Rietzschel

1

1 reference

26 August 2017

Marc De Buyzere

series ordinal

2

1 reference

26 August 2017

publication date

1 February 2012

1 reference

26 August 2017

published in

Biomarkers in Medicine

1 reference

26 August 2017

volume

6

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

19-34

1 reference

C-reactive protein: a critical update

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein, inflammation, and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Generation of C-reactive protein and complement components in atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein: how conformational changes influence inflammatory properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Human C-reactive protein does not promote atherosclerosis in transgenic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Role of C-reactive protein in cerebrovascular disease: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and all-cause mortality in a large hospital-based cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and its role in metabolic syndrome: mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

A general cardiovascular risk profile: The Framingham study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

General cardiovascular risk profile for use in primary care: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Screening for cardiovascular risk in asymptomatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Multiple biomarkers for the prediction of first major cardiovascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

High-sensitivity C-reactive protein and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Plasma C-reactive protein and risk of cancer: a prospective study from Greece.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein and colorectal cancer risk: a systematic review of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

21 January 2018

Diet and inflammation

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

A daily glass of red wine: does it affect markers of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Black tea reduces uric acid and C-reactive protein levels in humans susceptible to cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Human CRP Gene Polymorphism Influences CRP Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Association between C-reactive protein and features of the metabolic syndrome: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.108

21 January 2018

Identifiers

DOI

10.2217/BMM.11.108

1 reference

26 August 2017

1 reference